Introduction {#s1}
============

*Streptococcus pyogenes* (*S. pyogenes*), or group A streptococcus, is a pathogen which causes localized illness, such as pharyngitis and skin lesions \[[@R01]\]. *S. pyogenes* can asymptomatically colonize humans, and may cause invasive diseases, such as bacteremia, pneumonia, necrotizing fasciitis, and streptococcal toxic shock syndrome \[[@R01], [@R02]\].

*S. pyogenes* accounts for 2-5% of cases of bacterial pneumonia in the early 20th century \[[@R03]\]. Fatality of pneumonia due to *S. pyogenes* decreased to a low level after the advent of antibiotics \[[@R04]\]. Sporadic outbreaks of *S. pyogenes* infection have been reported mainly in military camps, and *S. pyogenes* rarely causes pneumonia in general \[[@R05]\]. However, an outbreak of *S. pyogenes* pneumonia occurred at a US military camp in 2002 \[[@R06]\]. This outbreak ended after intramuscular benzathine penicillin or oral azithromycin administration, suggesting that the potential for an epidemic of *S. pyogenes* infection cannot be ignored.

We present here a sporadic case of *S. pyogenes* pneumonia. A patient was admitted to our hospital to thoroughly investigate the cause of a persistent fever of unknown origin. Chest X-ray findings were unremarkable, and plain computed tomography (CT) of the chest showed bronchopneumonia in the right upper lobe of the lung. Notably, *S. pyogenes* was detected from sputum and blood culture samples on admission. Our patient was discharged from our hospital after 6 g/day of aminobenzylpenicillin administration for 10 days.

Case Report {#s2}
===========

A 78-year-old Japanese man was admitted to our hospital because of a fever lasting for 4 days. He had no relevant past history, except for lung tuberculosis in his 20s, and had no family history. He had taken no medications. He had smoked 10 cigarettes a day for approximately 60 years, but did not consume alcohol. Four days before admission, he suddenly had a fever (39.4 °C) with a sore throat and chills. He went to his home doctor for a check-up and underwent an influenza antigen test, but the result was negative. Oral acetaminophen was prescribed, but his fever persisted. He visited his home doctor again 2 days before admission and had a blood test, which showed that his white blood cell (WBC) count and C-reactive protein (CRP) level were elevated (12,400/mm^3^ and 16.01 mg/dL, respectively.) Although oral cefcapene pivoxil (300 mg/day) was added, his fever did not improve, and he was then admitted to our hospital.

On admission, his height was 165 cm, weight was 65.8 kg, body temperature was 38.3 °C, and blood pressure was 150/75 mm Hg. His heart rate was 90 beats per minute and regular. A physical examination showed no major abnormalities, except for mild pharyngeal erythema due to pharyngitis, and mildly increased sputum excretion. His arterial blood O~2~ saturation (98%) and partial O~2~ pressure (92.1 Torr) in room air were normal. A chest X-ray film showed granular shadows that were predominantly distributed in the bilateral lower lung field ([Fig. 1](#F1){ref-type="fig"}). An abdominal X-ray film and an electrocardiogram were normal. Laboratory tests showed a high WBC count of 11.6 × 10^9^ cells/L (normal: 3.5 - 9.0 × 10^9^ cells/L), lactate dehydrogenase concentration of 226 U/L (normal: 124 - 222 U/L), blood urea nitrogen concentration of 25.4 mg/dL (normal: 8 - 20 mg/dL), and CRP concentration of 16.33 mg/dL (normal: \< 0.3 mg/dL). All of these variables were above the normal range. Urinary findings were normal. Rapid antigen tests for influenza, pneumococcus, and mycoplasma were negative. Therefore, ultrasonography of the abdomen was performed, but no major abnormalities were observed. Echocardiography also showed no abnormalities. Subsequently, plain CT of the chest and the abdomen was performed, and this showed bronchial wall thickening in an upper lobe of the right lung, which was not evident on a chest X-ray film ([Fig. 2](#F2){ref-type="fig"}). Sputum culture samples for general and acid-fast bacteria and blood culture samples were collected soon after admission. He was initially diagnosed with bronchopneumonia. Intravenous administration of levofloxacin (LVFX, 500 mg/day) and ampicillin/sulbactam (ABPC/SBT, 6 g/day) was started.

![A chest X-ray film on admission. Multiple granular shadows predominantly distributed in the lower lung field, and thickening of the right interlobar pleura were observed. These findings had been pointed since the patient had had been infected with tuberculosis. No obvious findings suggesting pneumonia were observed.](jocmr-08-831-g001){#F1}

![A plain computed tomography image of the lung on admission. Increased density around the lobar bronchi in the right upper lobe of the lung, which suggested bronchopneumonia (white arrow), and emphysematous changes in both lungs were observed.](jocmr-08-831-g002){#F2}

On day 2, the patient's temperature started to fall. A sputum smear detected no obvious acid-fast bacteria. Notably, gram-positive cocci were detected in blood culture samples and these were identified as *S. pyogenes* on day 4. Moreover, *S. pyogenes* was detected from sputum culture samples. Streptococci that were detected from sputum and blood culture samples showed the same antibiotic susceptibility and were sensitive to LVFX and ABPC. On day 5, his temperature returned to normal and the WBC count was normalized (5.9 × 10^9^ cells/L). Therefore, administration of LVFX was terminated. With regard to sputum culture, species-specific polymerase chain reaction assays for acid-fast bacteria, including *Mycobacterium tuberculosis (M. tuberculosis), M. avium, M. intracellulare*, and *M. kansasii*, were negative. On day 9, his symptoms including fever, sore throat, and increased sputum excretion, completely resolved and the CRP level returned to normal (0.19 m/dL). Therefore, oral amoxicillin (750 mg/day) was substituted for intravenous administration of LVFX and ABPC/SBT on day 10. He was discharged from our hospital on day 10 and took oral amoxicillin for 10 days. No exacerbation was observed thereafter. Image findings of bronchopneumonia disappeared on plain chest CT 1 month after discharge. The patient was lost to follow-up after this time.

Discussion {#s3}
==========

Pneumonia caused by *S. pyogenes* is an uncommon cause of community-acquired pneumonia, but it may show a high mortality rate. Barnham et al \[[@R07]\] reviewed 17 cases of *S. pyogenes* pneumonia and reported its high mortality rate (47%), as well as a high detection rate (88%) of *S. pyogenes* from blood culture samples. They reported that 63% of patients who did not survive died within 1 day after hospitalization \[[@R07]\]. A recent study also showed a high mortality rate (20%) of *S. pyogenes* pneumonia, with half of the patients dying within 24 h after admission, and the detection rate of *S. pyogenes* from blood culture was 43% (17/40 cases) \[[@R08]\]. *S. pyogenes* pneumonia commonly occurs in winter and spring \[[@R07], [@R08]\]. Hypertension, chronic obstructive pulmonary disease, and diabetes have been reported as frequent comorbidities in patients with *S. pyogenes* pneumonia \[[@R07], [@R08]\]. With regard to complications of *S. pyogenes* pneumonia, pleural effusion, cavity formation in the lungs, septicemia, and septic shock have been reported \[[@R07], [@R08]\]. Symptoms mimicking scarlet fever, including desquamating rash, may be observed in rare cases \[[@R07]\]. Despite these serious conditions, there have been few other studies on the clinical presentation, prognosis, and characteristics of *S. pyogenes* pneumonia. To the best of our knowledge, 16 case reports describing patients with *S. pyogenes* pneumonia, including our case, have been published in the past three decades ([Table 1](#T1){ref-type="table"}) \[[@R09]\]. The duration from onset of *S. pyogenes* pneumonia to hospitalization varied from 1 to 9 days, and the mean duration was 4.8 ± 2.4 days. Among these 16 cases, six (38%) patients died after hospitalization \[[@R09], [@R13], [@R16], [@R19]\] and four of the six patients who did not survive died within 1 day after hospitalization \[[@R09], [@R16], [@R19], [@R20]\]. Blood culture samples were positive for *S. pyogenes* in 12 (75%) patients. With regard to the background of these patients, three had a history of respiratory illness (asthma, chronic obstructive pulmonary disease, and obsolete pulmonary tuberculosis) \[[@R10], [@R16]\], one underwent anti-tumor necrosis factor therapy using adalimumab for rheumatoid arthritis \[[@R20]\], one was an intravenous drug abuser \[[@R11]\], and one underwent thyroidectomy for treatment of thyroid cancer 5 days before onset of *S. pyogenes* pneumonia \[[@R18]\]. However, apart from these six patients having underlying diseases or risk factors of immunodeficiency, the remaining 10 (63%) patients were previously healthy. Moreover, based on duration from onset to hospitalization, the patients could be divided into two groups: 1) ≤ 5-day group (shorter than average duration, nine patients) and 2) \> 5-day group (longer than average duration, seven patients). In the ≤ 5-day group, three of nine (33%) patients died after hospitalization \[[@R09], [@R16], [@R21]\], while three of seven (43%) patients died in the \> 5-day group \[[@R13], [@R19], [@R20]\]. Interestingly, in the ≤ 5-day group, three patients showed co-infection of influenza B virus and *S. pyogenes*, and one of these three patients died \[[@R21], [@R22]\]. However, in the \> 5-day group, there was only one case of influenza A virus (IAV) infection. Acute viral tract infections can be associated with the occurrence of *S. pyogenes* pneumonia, reflecting virus-induced epithelial damage in the respiratory tract together with transient immune suppression \[[@R07]\]. Tamayo et al \[[@R08]\] also suggested the potential of influenza B virus for aggravation of *S. pyogenes* pneumonia. Therefore, physicians should be careful about preceding influenza virus infection in patients with *S. pyogenes* pneumonia.

###### Sixteen Adult Cases of *S. pyogenes* Pneumonia Reported in the Past Three Decades

  Author                           Year   Age (years), sex   Comorbidity                         Duration from onset to hospitalization   Blood pressure, pulse rate, and body temperature on admission   Administered antibiotics for initial treatment   Complication emerging after hospitalization                                 Blood culture-positive   Outcome
  -------------------------------- ------ ------------------ ----------------------------------- ---------------------------------------- --------------------------------------------------------------- ------------------------------------------------ --------------------------------------------------------------------------- ------------------------ ------------------------------------
  McMurray et al \[[@R09]\]        1987   33, female         \-                                  72 h                                     80/50 mm Hg, 120 bpm, 39 °C                                     ABPC + EM + MFIPC + GM                           Pleural effusion                                                            \-                       Dead on the day of hospitalization
  McIntyre et al \[[@R10]\]        1989   30, female         Bronchial asthma                    2 days                                   95/65 mm Hg, 100 bpm, 38.7 °C                                   ABPC                                             Lung abscess                                                                \+                       Alive
  McWhinney et al \[[@R11]\]       1991   26, male           Intravenous drug misuser            2 days                                   60/40 mm Hg, 60 bpm, 35 °C                                      EM + MFIPC                                       Pleural effusion, lung abscess                                              \+                       Alive
  Hamour et al \[[@R12]\]          1994   53, male           Herpes labialis, oral candidiasis   1 week                                   117/70 mm Hg, 120 bpm, 38 °C                                    CTX + EM + CPFX                                  Pleural effusion, atrial fibrillation and flutter, desquamating skin rash   \-                       Alive
  Brusch et al \[[@R13]\]          1996   51, male           \-                                  1 week                                   105/55 mm Hg, 130 bpm, 38.5 °C                                  VCM + EM + DOXY                                  Supraventricular tachycardia, multiple organ failure                        \-                       Dead on the second hospital day
  Kalima et al \[[@R14]\]          1998   35, female         Flu-A                               1 week                                   Unknown                                                         PC-G + CLDM                                      Pneumothorax, bronchopleural fistula                                        \+                       Alive
  Birch and Gowardman \[[@R15]\]   2000   33, male           \-                                  1 week                                   110/55 mm Hg, 130 bpm, 40.3 °C                                  CTX + EM                                         Pleural effusion, multiple organ failure, DIC                               \+                       Alive
  Taylor and Barkham \[[@R16]\]    2002   89, male           COPD, stroke                        2 days                                   140/100 mm Hg, pulse rate unknown, 38 °C                        CTRX                                             \-                                                                          \+                       Dead on the day of hospitalization
  Papadas et al \[[@R17]\]         2008   24, female         Tonsillitis                         9 days                                   Blood pressure and pulse rate unknown, 40 °C                    AMPC/CVA + CAM                                   \-                                                                          \+                       Alive
  Saldias et al \[[@R18]\]         2008   35, female         Thyroid cancer                      Within 1 day                             106/60 mm Hg, 90 bpm, 37.8 °C                                   CTRX + CLDM                                      Acute respiratory failure, septic shock                                     \+                       Alive
  Izumiyama et al \[[@R19]\]       2008   30, female         \-                                  1 week                                   70/40 mm Hg, 160 bpm, 37.6 °C                                   MEPM + MINO                                      Acute respiratory failure, septic shock                                     \+                       Dead 7 h after hospitalization
  Weinblatt et al \[[@R20]\]       2009   54, female         Rheumatoid arthritis                1 week                                   110/70 mm Hg, 110 bpm, 38.9 °C                                  CTRX + CLDM + VCM                                Acute respiratory failure, pneumothorax, septic shock                       \-                       Dead 8 h after hospitalization
  Abei et al \[[@R21]\]            2010   39, female         Flu-B                               3 days                                   Unknown                                                         PIPC/TAZ + CLDM                                  Acute respiratory failure, septic shock                                     \+                       Alive
  Abei et al \[[@R21]\]            2010   27, female         Flu-B                               3 days                                   Unknown                                                         AMPC/CVA + CAM                                   Acute respiratory failure, septic shock, pulmonary hemorrhage               \+                       Dead 18 days after hospitalization
  Lam et al \[[@R22]\]             2013   34, male           Flu-B                               5 days                                   Unknown                                                         MEPM + AZM + VCM                                 Septic shock, multiple organ failure                                        \+                       Alive
  Akuzawa (our case)               2016   78, male           Obsolete pulmonary tuberculosis     4 days                                   124/72 mm Hg, 96 bpm, 39.4 °C                                   ABPC/SBT                                         \-                                                                          \+                       Alive

ABPC: aminobenzylpenicillin; ABPC/SBT: aminobenzylpenicillin/sulbactam; AMPC/CVA: amoxicillin/clavulanic acid; CAM: clarithromycin; CLDM: clindamycin; COPD: chronic obstructive pulmonary disease; CPFX: ciprofloxacin; CTRX: ceftriaxone; AZM: azithromycin; CTX: cefotaxime; DIC: disseminated intravascular coagulation; DOXY: doxycycline; EM: erythromycin; GM: gentamycin; MEPM: meropenem; MFIPC: flucloxacillin; MINO: minocycline; PC-G: penicillin G; PIPC/TAZ: piperacillin/tazobactam; VCM: vancomycin.

Previous studies have shown that IAV infection facilitates *S. pyogenes* infection in the respiratory tract. IAV infection increases the abundance of fibrinogen 4 days after infection \[[@R01]\]. Fibrinogen is important for *S. pyogenes* adherence and internalization within epithelial cells via M protein, which is adhesion molecule on the streptococcal surface and triggers uptake of bacteria into the host cells \[[@R23]\]. Production of fibronectin, another important ligand for *S. pyogenes*, also increases during IAV infection \[[@R01]\]. On the other hand, viral hemagglutinin and neuraminidase also stimulate expression of adhesion molecules on the cell surface \[[@R01]\]. These findings suggest that IAV infection may promote *S. pyogenes* infection in the respiratory tract. The outcome of IAV and *S. pyogenes* co-infections in murine models varies depending on the specific viral and bacterial strains \[[@R01]\]. However, whether influenza B virus more rapidly deteriorates *S. pyogenes* infection than IAV is unclear because of a lack of adequate comparative studies. In addition, limitations of this report include our inability to determine the M protein serotype of the *S. pyogenes* strain detected from our patient. Additionally, we were unable to show the genetic identity of the *S. pyogenes* strains obtained from sputum and blood culture samples. Further research to determine other factors, including preceding viral infection other than influenza and mechanisms exacerbating *S. pyogenes* pneumonia, is required.

In conclusion, we present a case of *S. pyogenes* pneumonia. Although our patient's clinical course was good, our literature review showed a high mortality rate of *S. pyogenes* pneumonia (38%). Notably, 63% of the reviewed patients presenting with *S. pyogenes* pneumonia were previously healthy. A high detection rate (75%) of *S. pyogenes* from blood culture samples is also a characteristic in *S. pyogenes* pneumonia. Although *S. pyogenes* is not a major pathogen of community-acquired pneumonia, physicians should be aware of its characteristics.
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